Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...
US must meet tougher standard in Regeneron kickback lawsuit
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
JD Supra2h
Narrowing FCA Cases Based on Kickback Allegations: What Healthcare and Life Sciences Companies Need to Know About the Regeneron Decision
On February 18, 2025, in a closely watched decision, the United States Court of Appeals for the First Circuit in United States v.
GlobalData on MSN6d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's third consecutive day of gains.
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman
Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
JD Supra3d
False Claim Act Liability Under Anti-Kickback Statute Requires But-For Causation: First Circuit Narrows Liability in Growing Circuit Split
On February 18, 2025, the First Circuit Court of Appeals issued its decision in U.S. v. Regeneron Pharmaceuticals, ruling ...
Fat, not muscle: drugmakers in race for next weight-loss breakthrough
European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...
This Company Just Initiated a Quarterly Dividend: Time to Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Regeneron Pharmaceuticals, Inc. (REGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Yahoo Finance6d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...